Research and development of disease model mice, biomarkers, and personalized medicine technologies
First written in FY2016. 16 of 22 entries say "Advanced", first in FY2018-Q1. Latest entry: 2026-09-07.
0 other companies' latest entry also says "Advanced".
- 2026-09-07AdvancedOther Disclosures
「Based on these results, we will consider the potential use of the technology in preclinical research evaluating effects on tissue deposition for nucleic acid drugs and gene therapies targeting human TTR, as well as drug candidates intended to stabilize TTR.」
The company's proprietary TTR exon-humanized mouse confirmed TTR deposition in multiple tissues, including peripheral nerves, demonstrating its potential use in elucidating disease pathology with disease models and in the preclinical evaluation of drug candidates. This represents a specific advance in the canonical thread t14 concerning research and development of disease-model mice and related products. - FY2026AdvancedAnnual report
「In the carcinogenicity-related field, we began accepting contracts for short-term carcinogenicity testing using rasH2 mice, which has attracted attention as an alternative to conventional 2-year long-term carcinogenicity testing. Before beginning the service, we established background data for rasH2 mice and strengthened our data evaluation system. We also began accepting contracts for medium-term colorectal carcinogenicity testing using rats for which background data had been established.」
In addition to beginning contract services for short-term carcinogenicity testing using rasH2 mice and medium-term colorectal carcinogenicity testing using rats, progress was made in establishing background data and strengthening the evaluation system. - FY2026-H1AdvancedAnnual report
「At 株式会社トランスジェニック, we worked to expand high-value-added new services, including short-term carcinogenicity testing using rasH2 mice, which enables carcinogenicity to be evaluated in a shorter period than conventional long-term carcinogenicity testing, medium-term skin carcinogenicity testing, for which contract services began in 2024, and medium-term colorectal carcinogenicity testing using rats, for which we began accepting contracts.」
In addition to short-term carcinogenicity testing using rasH2 mice, for which the technology was established and preparations to begin accepting contracts were reported in the previous fiscal year, we advanced the expansion of high-value-added services, including the launch of contract services for medium-term skin carcinogenicity testing and medium-term colorectal carcinogenicity testing using rats. - FY2025AdvancedAnnual report
「We began providing contract services for “medium-term carcinogenicity testing,” which evaluates the carcinogenicity of chemicals over a short period as part of chemical safety testing. We also established the technology for short-term carcinogenicity testing using rasH2 mice by oral administration, an area with strong demand related to carcinogenicity, and advanced preparations to begin accepting contracts.」
We began providing contract services for medium-term carcinogenicity testing and advanced preparations to begin accepting contracts after establishing the technology for short-term carcinogenicity testing using rasH2 mice by oral administration. - FY2024AdvancedAnnual report
「At our subsidiary 株式会社安評センター, we are introducing and conducting research and development on highly versatile disease model mice using genetic modification technology, with the aim of expanding the clinical testing business while broadening the lineup. Among these, “liver-humanized mice,” which reflect human organ function, are expected to be used in more accurate preclinical testing of drug efficacy and metabolism, and preparations for commercialization began in December 2023. We also established and began providing contract services for “medium-term carcinogenicity testing,” which predicts the carcinogenicity of chemicals with high accuracy over a short period as part of chemical safety testing. In addition, we are continuing joint research and development of transgenic zebrafish models, which have high extrapolative validity to humans and are expected to serve as a next-generation drug screening technology.」
Several specific developments were reported in expanding the disease model lineup, including preparations to commercialize liver-humanized mice, the launch of medium-term carcinogenicity testing services, and the continuation of joint research on transgenic zebrafish. - FY2021AdvancedAnnual report
「During the consolidated fiscal year, use of Muta mice, which detect mutations, progressed smoothly in genotoxicity testing at our subsidiary, 株式会社安評センター.」
Regarding the use of disease and functional model mice in the business, Muta mice are being used smoothly in genotoxicity testing at 安評センター. - FY2020AdvancedAnnual report
「During the consolidated fiscal year, we expanded the use of biological stress visualization mice and atopic dermatitis models in preclinical testing at our subsidiary, 株式会社新薬リサーチセンター.」
For disease model mice, we expanded their use in preclinical testing at our subsidiary, beyond simply selling and introducing them. - FY2019AdvancedAnnual report
「With the aim of expanding the business using highly versatile disease model mice, we worked to introduce, develop, and increase production of various model mice, including Alzheimer’s disease model mice, mental and neurological disease model mice, and non-alcoholic steatohepatitis model mice, for use in contract preclinical testing at our subsidiary 株式会社新薬リサーチセンター. For atopic dermatitis model mice and biological stress visualization mice, we began sales of individual animals in addition to making them available for contract preclinical testing.」
We advanced the introduction, development, and increased production of multiple disease model mice, and began sales of atopic dermatitis model mice and biological stress visualization mice. - FY2019-Q3AdvancedAnnual report
「To secure further orders for preclinical testing and meet the diverse needs of customers, primarily pharmaceutical companies, we began selling new disease models, including “biological stress visualization mice” and “atopic dermatitis model mice,” further expanding the lineup. We also worked to use model mice in preclinical testing, including through a business alliance with 京ダイアグノスティクス株式会社, which produces PDSX for use in preclinical testing.」
In addition to beginning sales of biological stress visualization mice and atopic dermatitis model mice, we expanded the disease model lineup and its use in preclinical testing through a business alliance with a PDSX production company. - FY2019-Q2RestatedAnnual report
「To secure further orders for preclinical testing and meet the diverse needs of customers, primarily pharmaceutical companies, 株式会社トランスジェニック began selling new disease models, including “biological stress visualization mice” and “atopic dermatitis model mice.” In addition to further expanding the lineup, we worked to use model mice in preclinical testing.」
Sales of biological stress visualization mice and atopic dermatitis model mice, as well as their use in preclinical testing, are ongoing. - FY2019-Q1AdvancedAnnual report
「To secure further orders for preclinical testing and meet the diverse needs of customers, primarily pharmaceutical companies, 株式会社トランスジェニック began selling new disease models, including “biological stress visualization mice” and “atopic dermatitis model mice.” In addition to further expanding the lineup, we worked to use model mice in preclinical testing.」
Sales began for biological stress visualization mice and atopic dermatitis model mice as new disease models, and efforts advanced to expand the model mouse lineup and use the mice in preclinical testing. - FY2018-Q3AdvancedAnnual report
「We also entered into license agreements for APPOSK mice and wild-type TAU transgenic mice as Alzheimer’s disease models, mental and neurological disease model mice, and AIM-deficient mice as non-alcoholic steatohepatitis (NASH) model mice, thereby expanding our lineup of model mice, which are in high demand.」
In addition to central nervous system models, we entered into a license agreement for AIM-deficient mice as NASH models, expanding our range of model mice. We also described efforts to use these mice in preclinical testing through our CRO business. - FY2018-Q2AdvancedAnnual report
「We also entered into license agreements for APPOSK mice and wild-type TAU transgenic mice as Alzheimer’s disease models, as well as for mental and neurological disease model mice, thereby expanding our lineup of central nervous system model mice, which are in high demand.」
The lineup of model mice was expanded through license agreements for APPOSK mice, wild-type TAU transgenic mice, and mental and neurological disease model mice. - FY2018-Q1AdvancedAnnual report
「We entered into license agreements with Osaka City University and Professor Hiroshi Mori (森 啓), Specially Appointed Professor, for the APPOSK mice developed by Professor Mori and others as an Alzheimer’s disease model, and for wild-type TAU transgenic mice, thereby expanding our lineup of central nervous system model mice, which are in high demand.」
The lineup of central nervous system models was expanded through the licensing of APPOSK mice and wild-type TAU transgenic mice for the research, development, and commercialization of disease model mice. - FY2017RestatedAnnual report
「We have pursued joint research on the “development of humanized mice” with Kumamoto University, a national university corporation, since December 2010, with the aim of establishing and commercializing disease models that enable the development of highly versatile new therapies.」
Research and development of humanized mice, disease model mice, and biomarkers and companion diagnostics is ongoing. - FY2017-Q3RestatedAnnual report
「The company also conducted research and development of new disease models to meet the diverse needs of customers, primarily pharmaceutical companies, and expand orders for nonclinical testing.」
The company continues research and development of new disease models to expand orders for nonclinical testing. - FY2017-Q2RestatedAnnual report
「The company also conducted research and development of new disease models to meet the diverse needs of customers, primarily pharmaceutical companies, and expand orders for nonclinical testing.」
The company continues research and development of new disease models to expand orders for nonclinical testing. - FY2017-Q1RestatedAnnual report
「The company also conducted research and development of new disease models to meet the diverse needs of customers, primarily pharmaceutical companies, and expand orders for nonclinical testing.」
The company continues research and development of new disease models to expand orders for nonclinical testing. - FY2016First statedAnnual report
「To evaluate the efficacy of new drugs and develop optimal disease model systems, the company concluded a joint research agreement with Kumamoto University in December 2010 concerning the development of humanized mice and continued working on the development of liver-humanized mice. It also proceeded with the introduction and expanded production of various disease model mice, including models for atopic dermatitis and dementia, and the production of frozen embryos for use in nonclinical testing services at its subsidiary, ㈱新薬リサーチセンター.」
The company seeks to strengthen its business base through the research and development of liver-humanized mice, various disease model mice, depression markers, and companion diagnostics.